Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Seeking Alpha

15 Jun 2026, 19:52 UTC · 1h ago

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Read original · https://seekingalpha.com/article/4915129-lexeo-therapeutics-inc-lxeo-shareholder-analyst-call-transcript

Free · No account

Track these names every morning.

Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.

We’ll watch

#biotech#earnings_call#pharmaceuticals#transcript

Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.

Free forever · one email a day, max · unsubscribe in one click.How it works

How the impact breaks down

Where the story's weight lands

Impact by category

Sector Rotation+0.100

Biggest drivers

Healthcare+0.100

6 related stories

Business Wire
50m ago
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- biotech
- pharmaceuticals
Read

Lexeo Therapeutics, Inc. (LXEO) Shareh… | NewsImpactScreener

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript

Track these names every morning.

Impact by category

Biggest drivers

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript

Track these names every morning.

Impact by category

Biggest drivers

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Most positively impacted

Most negatively impacted

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)

Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript

Track these names every morning.

Impact by category

Biggest drivers

Next reads from the same story arc

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript

Track these names every morning.

Impact by category

Biggest drivers

Next reads from the same story arc

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Most positively impacted

Most negatively impacted

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)

Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First